Key Takeaways:
Sino Biopharmaceutical Co. granted AstraZeneca Plc exclusive rights to develop and commercialize its experimental COPD drug TQC3721 outside China in a deal valued at as much as $1.9 billion, the latest cross-border licensing agreement that shows China's growing role in drug innovation.
"The combination of TQC3721's dual mechanism and Sino Biopharm's clinical data made this a compelling addition to our respiratory pipeline," said Iskra Reic, executive vice president of AstraZeneca's respiratory and immunology business unit.
Under the agreement, AstraZeneca will pay $200 million upfront, with additional payments tied to development and commercial milestones. TQC3721 is a PDE3/4 inhibitor designed to simultaneously open airways and reduce inflammation, targeting the roughly 300 million people worldwide living with chronic obstructive pulmonary disease. Sino Biopharmaceutical retains rights to the drug in China.
The deal is the second major out-licensing transaction for Sino Biopharmaceutical this year and comes as Chinese drugmakers sign record numbers of cross-border partnerships. Data from the National Medical Products Administration show the total value of China's out-licensing deals exceeded $60 billion in the first three months of 2026, nearly half the $135.7 billion recorded for all of 2025.
Chinese pharmaceutical companies signed more than 150 out-licensing agreements in 2025, with total deal value more than doubling from the prior year, according to industry database provider PharmCube. The structure of these transactions is shifting from single-asset licensing toward broader platform partnerships, analysts at China Galaxy Securities said.
The 2026 Government Work Report identified biopharmaceuticals as an emerging pillar industry for the first time, placing it alongside integrated circuits and aerospace. A revised drug administration regulation taking effect May 15 introduces six-year regulatory data protection and seven-year market exclusivity for rare-disease drugs, measures analysts say could further boost China's attractiveness for global drug development partnerships.
For Sino Biopharmaceutical, the deal validates its internal research capabilities and provides a significant revenue stream beyond its core generic drug business. The company is eligible for royalties on future sales, though specific royalty rates were not disclosed. Investors will watch for potential milestone payments and clinical data readouts as TQC3721 advances through development under AstraZeneca's oversight.
This article is for informational purposes only and does not constitute investment advice.
